Aarti Drugs Limited (BOM:524348)

Market Cap	33.56B
Revenue (ttm)	23.30B
Net Income (ttm)	1.53B
Shares Out	91.94M
EPS (ttm)	16.69
PE Ratio	21.87
Forward PE	23.55
Dividend	1.00 (0.28%)
Ex-Dividend Date	Feb 4, 2025

Volume	36,136
Average Volume	20,322
Open	363.80
Previous Close	359.20
Day's Range	359.75 - 365.90
52-Week Range	312.50 - 634.90
Beta	0.70
RSI	56.30
Earnings Date	Apr 30, 2025

About Aarti Drugs

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, ti...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1984
• Employees: 1,064
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524348

Financial Performance

In 2023, Aarti Drugs's revenue was 25.29 billion, a decrease of -6.90% compared to the previous year's 27.16 billion. Earnings were 1.71 billion, an increase of 3.07%.